Ajanta Pharma Limited (NSE:AJANTPHARM)
India
· Delayed Price · Currency is INR 2,936.40
-55.60 (-1.86%)
At close: Mar 9, 2026
Ajanta Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 52,016 | 46,481 | 42,087 | 37,426 | 33,410 | 28,897 | Upgrade
|
| Revenue Growth (YoY) | 14.78% | 10.44% | 12.45% | 12.02% | 15.62% | 11.66% | Upgrade
|
| Cost of Revenue | 12,345 | 11,429 | 11,210 | 11,102 | 8,840 | 6,832 | Upgrade
|
| Gross Profit | 39,671 | 35,052 | 30,877 | 26,324 | 24,570 | 22,065 | Upgrade
|
| Selling, General & Admin | 12,453 | 11,048 | 9,122 | 7,978 | 6,571 | 5,523 | Upgrade
|
| Other Operating Expenses | 13,027 | 11,279 | 9,944 | 10,241 | 8,667 | 6,478 | Upgrade
|
| Operating Expenses | 27,156 | 23,768 | 20,420 | 19,527 | 16,491 | 13,162 | Upgrade
|
| Operating Income | 12,516 | 11,285 | 10,457 | 6,798 | 8,079 | 8,903 | Upgrade
|
| Interest Expense | -198.2 | -207.3 | -72.1 | -58.4 | -102 | -82.7 | Upgrade
|
| Interest & Investment Income | 471.6 | 471.6 | 277.1 | 84.6 | 146.5 | 35.1 | Upgrade
|
| Currency Exchange Gain (Loss) | 73.4 | 282.1 | 158.7 | 660.7 | 563.7 | 45.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 118 | 41.4 | 264.1 | 61.5 | 323.8 | 40.9 | Upgrade
|
| EBT Excluding Unusual Items | 12,980 | 11,872 | 11,084 | 7,546 | 9,011 | 8,941 | Upgrade
|
| Gain (Loss) on Sale of Investments | 25.2 | 25.2 | 20.1 | -40 | 122.8 | 82.7 | Upgrade
|
| Gain (Loss) on Sale of Assets | -6 | -6 | 34.9 | -53.5 | -38.7 | -22.1 | Upgrade
|
| Pretax Income | 13,000 | 11,892 | 11,139 | 7,453 | 9,095 | 9,002 | Upgrade
|
| Income Tax Expense | 2,854 | 2,688 | 2,978 | 1,573 | 1,968 | 2,463 | Upgrade
|
| Net Income | 10,146 | 9,204 | 8,162 | 5,880 | 7,127 | 6,539 | Upgrade
|
| Net Income to Common | 10,146 | 9,204 | 8,162 | 5,880 | 7,127 | 6,539 | Upgrade
|
| Net Income Growth | 13.00% | 12.77% | 38.81% | -17.50% | 8.99% | 39.80% | Upgrade
|
| Shares Outstanding (Basic) | 125 | 125 | 126 | 128 | 130 | 131 | Upgrade
|
| Shares Outstanding (Diluted) | 125 | 125 | 126 | 128 | 130 | 131 | Upgrade
|
| Shares Change (YoY) | -0.41% | -0.66% | -1.65% | -1.19% | -0.74% | -0.21% | Upgrade
|
| EPS (Basic) | 81.22 | 73.56 | 64.82 | 45.89 | 54.97 | 50.06 | Upgrade
|
| EPS (Diluted) | 81.21 | 73.53 | 64.77 | 45.89 | 54.96 | 50.06 | Upgrade
|
| EPS Growth | 13.47% | 13.53% | 41.14% | -16.50% | 9.79% | 40.09% | Upgrade
|
| Free Cash Flow | - | 8,393 | 6,327 | 6,176 | 4,129 | 4,047 | Upgrade
|
| Free Cash Flow Per Share | - | 67.05 | 50.21 | 48.20 | 31.84 | 30.98 | Upgrade
|
| Dividend Per Share | 28.000 | 28.000 | 36.000 | 7.000 | 6.333 | 6.333 | Upgrade
|
| Dividend Growth | - | -22.22% | 414.29% | 10.53% | - | -26.92% | Upgrade
|
| Gross Margin | 76.27% | 75.41% | 73.36% | 70.34% | 73.54% | 76.36% | Upgrade
|
| Operating Margin | 24.06% | 24.28% | 24.84% | 18.16% | 24.18% | 30.81% | Upgrade
|
| Profit Margin | 19.50% | 19.80% | 19.39% | 15.71% | 21.33% | 22.63% | Upgrade
|
| Free Cash Flow Margin | - | 18.06% | 15.03% | 16.50% | 12.36% | 14.01% | Upgrade
|
| EBITDA | 13,796 | 12,522 | 11,638 | 7,952 | 9,173 | 9,889 | Upgrade
|
| EBITDA Margin | 26.52% | 26.94% | 27.65% | 21.25% | 27.46% | 34.22% | Upgrade
|
| D&A For EBITDA | 1,280 | 1,238 | 1,181 | 1,154 | 1,094 | 985.9 | Upgrade
|
| EBIT | 12,516 | 11,285 | 10,457 | 6,798 | 8,079 | 8,903 | Upgrade
|
| EBIT Margin | 24.06% | 24.28% | 24.84% | 18.16% | 24.18% | 30.81% | Upgrade
|
| Effective Tax Rate | 21.95% | 22.60% | 26.73% | 21.10% | 21.64% | 27.36% | Upgrade
|
| Revenue as Reported | 53,304 | 47,426 | 42,933 | 38,413 | 34,567 | 29,157 | Upgrade
|
| Advertising Expenses | - | 57.6 | 44.9 | 50.2 | 47.8 | 16.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.